Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib + Pembrolizumab + SOC in Advanced Solid Tumors (EC and PDAC)
NCT05945823Phase 2Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Jul 2023
- Primary completion
- Oct 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of futibatinib in esophageal cancer, pancreatic ductal adenocarcinoma (PDAC), sponsored by Taiho Oncology. Started Jul 2023; status: active, not recruiting.
02
Drugs
futibatinib
03
Conditions
esophageal cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05945823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945823.